Research programme: CTLA-4/FasL fusion protein - KAHR MedicalAlternative Names: KAHR-102
Latest Information Update: 19 Dec 2015
At a glance
- Originator KAHR Medical
- Class Proteins
- Mechanism of Action Apoptosis stimulants; CD80 antigen inhibitors; CD86 antigen inhibitors; CD95 antigen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer